The study adds to growing evidence that immunotherapy and chemoembolization prolong progression-free survival.

But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...

The approval was based on data from the phase 2 IMCgp100-202 trial that assessed Kimmtrak in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma. The Food and Drug ...

The Food and Drug Administration (FDA) has approved Imjudo (tremelimumab-actl) in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma (HCC). Imjudo is a ...

Natco Pharma and Lupin gained FDA approval for bioequivalent generic eribulin mesylate injection, potentially reducing ...

Impact of the COVID-19 pandemic on care delivery and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). A phase II trial combining tumor ...

SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.

SAN FRANCISCO -- Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a chemoimmunotherapy combination, a small ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults ...

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement ...